Ophthalmology Deals Up 1100% in 2026 — Here's the Data

Ophthalmology deal activity surged 1100% in the six months ending September 22, 2026, compared to the prior half-year period — climbing from 1 tracked deal to 12. That is not a rounding error. Between September 2025 and March 2026, the therapeutic area was essentially dormant on the licensing front. Then, in rapid succession, five major transactions landed between April and June 2026, pulling in players as large as Biogen, AbbVie, Merck, and Johnson & Johnson. The driver is straightforward: Big Pharma has collectively realized that its ophthalmology pipelines are thin precisely when the market opportunity — gene therapies for inherited retinal diseases, next-generation complement inhibitors, sustained-delivery platforms — is accelerating past anti-VEGF monotherapy.

The Data — Ophthalmology Deal Activity, Period over Period

The contrast is stark. One deal across the entire back half of 2025 into early 2026, then a cascade of twelve in the following six months. When you cross-reference this against Deal Benchmarks for other therapeutic areas over the same window, ophthalmology moved from the bottom quartile of deal volume to the top five — outpacing even neuroscience on a percentage-change basis. This is not incremental growth. This is a market inflection.

What's Driving the Trend

Three forces converged to create the ophthalmology licensing 2026 surge. First, pipeline scarcity at scale. The anti-VEGF market — dominated by Eylea, Lucentis, and their biosimilars — is mature. Regeneron's Eylea franchise faces intensifying biosimilar competition, and no single large pharma company has a credible next-generation retinal platform positioned for approval before 2029. When Biogen paid $5.6B for Apellis, it was buying the only scaled commercial complement franchise in ophthalmology (Syfovre for geographic atrophy). That kind of scarcity inflates valuations and compresses timelines. BD teams that waited got outbid.

Second, gene therapy validation. The MeiraGTx–J&J deal ($130M upfront) and the REGENXBIO–AbbVie partnership both center on AAV-based gene therapies for retinal conditions. After years of clinical setbacks industry-wide, recent data readouts have restored confidence that subretinal and intravitreal gene delivery can produce durable, one-time treatment effects. AbbVie's move is particularly telling — the company already holds a dominant position in immunology and aesthetics, and its decision to build in ophthalmology via gene therapy signals a long-term strategic commitment, not an opportunistic bolt-on.

Third, regulatory tailwinds. The FDA's expedited review pathways for rare ophthalmic diseases (RPE65 mutations, achromatopsia, XLRP) have shortened timelines enough to make gene therapy assets financeable and partnerable. The agency's willingness to accept functional visual endpoints — not just anatomical OCT measures — has reduced development risk in a way that was not true even two years ago. Combined with CMS reimbursement precedents set by Luxturna, the commercial model for high-priced, single-administration retinal therapies is now proven enough for pharma CFOs to approve nine-figure upfronts.

Notable Deals

The Apellis–Biogen deal is the headline. At $5.6B total deal value with what appears to be an all-cash structure, it represents the largest ophthalmology transaction since Roche's Spark Therapeutics acquisition in 2019 — and it dwarfs that deal in absolute terms. Biogen needed a commercial-stage asset to offset its neuroscience concentration risk after Leqembi's slower-than-expected launch. Apellis gave it a growing GA franchise and a complement biology platform with optionality beyond the eye. The deal tells you that ophthalmology deal trends 2026 are not about small option-style bets — acquirers are writing large checks for de-risked assets.

The MeiraGTx–J&J deal ($130M upfront) sits at the other end of the risk spectrum: preclinical-to-Phase-I gene therapy programs for inherited retinal diseases. J&J's surgical ophthalmology footprint (via Johnson & Johnson Vision) provides a distribution and surgical delivery advantage that pure-play biotechs cannot replicate. This deal structure — significant upfront with milestone-heavy backend — is becoming the template for ophthalmology licensing 2026 in gene therapy. Compare that to the REGENXBIO–AbbVie and EyeBio–Merck deals, where financial terms were undisclosed but likely involve option-based or milestone-gated structures given the earlier-stage nature of the assets.

AbbVie's deal with Aldeyra Therapeutics deserves attention for a different reason. Aldeyra's RASP (reactive aldehyde species) platform targets dry eye and other ocular surface diseases — a crowded market where differentiation is notoriously difficult. AbbVie's bet here suggests it sees the ocular surface as a high-volume, primary-care-adjacent commercial opportunity complementary to its aesthetics franchise (Allergan). This is a portfolio strategy play, not a pipeline-gap play.

What This Means for BD Teams Right Now

This is a seller's market — and it will remain one through at least Q1 2027. Here is why: the number of acquirers with stated ophthalmology ambitions (Biogen, AbbVie, J&J, Merck, Roche) exceeds the number of clinical-stage assets available for licensing. That imbalance compresses diligence timelines and inflates upfronts. If you are a biotech with a Phase II or later ophthalmology asset, you should be running a competitive process now, not waiting for Phase III data to mature.

For buy-side teams, the window to acquire complement, gene therapy, or sustained-delivery assets at reasonable multiples is closing. The Apellis deal will recalibrate every comparable valuation in the space. If you are benchmarking a target against pre-2026 ophthalmology transactions, your model is already stale — use Deal Benchmarks to recalibrate against the current cycle. Specifically, expect upfront-to-TDV ratios to compress: licensors are demanding higher upfront percentages (40–60% of TDV vs. the historical 20–30% average in ophthalmology) because they have leverage and multiple bidders.

Deal structures are shifting accordingly. Option deals with modest upfronts — common in 2023–2024 — are losing favor with licensors who can command competitive term sheets. We are seeing a return to traditional licensing with $100M+ upfronts and double-digit royalties on commercial sales, particularly for retinal assets. Gene therapy deals are the exception: the binary clinical risk profile still supports milestone-gated structures, but even here, upfront payments are 2–3x what they were 18 months ago for comparable-stage programs.

The bottom line: ophthalmology has moved from a niche therapeutic area to a Tier 1 BD priority for at least five top-20 pharma companies simultaneously. That has not happened since the anti-VEGF era began in 2005.

Benchmark your deal against current market rates. Use the Ambrosia calculator to stress-test your upfront, milestones, and royalty structure against the latest ophthalmology comparables — including the 2026 transactions reshaping the market right now.